BioCardia Management

Management criteria checks 3/4

BioCardia's CEO is Peter Altman, appointed in Jan 2002, has a tenure of 22.17 years. total yearly compensation is $901.90K, comprised of 58.9% salary and 41.1% bonuses, including company stock and options. directly owns 2.14% of the company’s shares, worth $232.79K. The average tenure of the management team and the board of directors is 5.7 years and 7.4 years respectively.

Key information

Peter Altman

Chief executive officer

US$901.9k

Total compensation

CEO salary percentage58.9%
CEO tenure22.2yrs
CEO ownership2.1%
Management average tenure5.7yrs
Board average tenure7.4yrs

Recent management updates

Here's Why BioCardia, Inc.'s (NASDAQ:BCDA) CEO Compensation Is The Least Of Shareholders Concerns

Oct 12
Here's Why BioCardia, Inc.'s (NASDAQ:BCDA) CEO Compensation Is The Least Of Shareholders Concerns

Recent updates

Here's Why BioCardia, Inc.'s (NASDAQ:BCDA) CEO Compensation Is The Least Of Shareholders Concerns

Oct 12
Here's Why BioCardia, Inc.'s (NASDAQ:BCDA) CEO Compensation Is The Least Of Shareholders Concerns

BioCardia stock rises on contract for delivery products for BlueRock's cell therapies

Aug 24

Will BioCardia (NASDAQ:BCDA) Spend Its Cash Wisely?

Aug 24
Will BioCardia (NASDAQ:BCDA) Spend Its Cash Wisely?

Here's Why We're Watching BioCardia's (NASDAQ:BCDA) Cash Burn Situation

May 10
Here's Why We're Watching BioCardia's (NASDAQ:BCDA) Cash Burn Situation

We Think BioCardia (NASDAQ:BCDA) Needs To Drive Business Growth Carefully

Jan 06
We Think BioCardia (NASDAQ:BCDA) Needs To Drive Business Growth Carefully

We Think BioCardia (NASDAQ:BCDA) Needs To Drive Business Growth Carefully

Sep 23
We Think BioCardia (NASDAQ:BCDA) Needs To Drive Business Growth Carefully

Why I've Taken A Small Position In BioCardia

Jun 14

Shareholders May Not Be So Generous With BioCardia, Inc.'s (NASDAQ:BCDA) CEO Compensation And Here's Why

Jun 08
Shareholders May Not Be So Generous With BioCardia, Inc.'s (NASDAQ:BCDA) CEO Compensation And Here's Why

Is BioCardia (NASDAQ:BCDA) In A Good Position To Deliver On Growth Plans?

May 20
Is BioCardia (NASDAQ:BCDA) In A Good Position To Deliver On Growth Plans?

BioCardia issued U.S. patent for Helix Biotherapeutic Delivery system

Dec 30

BioCardia slips 11% on launch of direct offering

Dec 16

BioCardia says DSMB feedback on cell therapy data in heart failure study anticipated soon

Dec 14

What We Learned About BioCardia's (NASDAQ:BCDA) CEO Compensation

Dec 14
What We Learned About BioCardia's (NASDAQ:BCDA) CEO Compensation

CEO Compensation Analysis

How has Peter Altman's remuneration changed compared to BioCardia's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2023n/an/a

-US$13m

Jun 30 2023n/an/a

-US$13m

Mar 31 2023n/an/a

-US$12m

Dec 31 2022US$902kUS$531k

-US$12m

Sep 30 2022n/an/a

-US$12m

Jun 30 2022n/an/a

-US$12m

Mar 31 2022n/an/a

-US$13m

Dec 31 2021US$1mUS$488k

-US$13m

Sep 30 2021n/an/a

-US$12m

Jun 30 2021n/an/a

-US$13m

Mar 31 2021n/an/a

-US$13m

Dec 31 2020US$883kUS$380k

-US$15m

Sep 30 2020n/an/a

-US$16m

Jun 30 2020n/an/a

-US$15m

Mar 31 2020n/an/a

-US$16m

Dec 31 2019US$747kUS$363k

-US$15m

Sep 30 2019n/an/a

-US$15m

Jun 30 2019n/an/a

-US$15m

Mar 31 2019n/an/a

-US$14m

Dec 31 2018US$1mUS$360k

-US$14m

Sep 30 2018n/an/a

-US$14m

Jun 30 2018n/an/a

-US$13m

Mar 31 2018n/an/a

-US$13m

Dec 31 2017US$372kUS$310k

-US$12m

Compensation vs Market: Peter's total compensation ($USD901.90K) is above average for companies of similar size in the US market ($USD662.11K).

Compensation vs Earnings: Peter's compensation has been consistent with company performance over the past year.


CEO

Peter Altman (56 yo)

22.2yrs

Tenure

US$901,897

Compensation

Dr. Peter A. Altman, Ph.D. has been Chief Executive Officer and President of BioCardia, Inc. since 2002. Dr. Altman served as an acting Chief Executive Officer of Lumen Therapeutics from 2004 to 2005. He s...


Leadership Team

NamePositionTenureCompensationOwnership
Peter Altman
CEO, President & Director22.2yrsUS$901.90k2.14%
$ 232.8k
David McClung
Chief Financial Officer8yrsUS$565.10k0.52%
$ 56.9k
Edward Gillis
Senior Vice President of Devices3.4yrsUS$389.70k0.19%
$ 20.5k
Sujith Shetty
Chief Medical Officer and VP of Clinical & Regulatory3.1yrsno datano data

5.7yrs

Average Tenure

60yo

Average Age

Experienced Management: BCDA's management team is seasoned and experienced (5.7 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Peter Altman
CEO, President & Director22.2yrsUS$901.90k2.14%
$ 232.8k
Jay Moyes
Independent Director13.2yrsUS$76.80k0.20%
$ 21.3k
Richard Krasno
Independent Director7.4yrsUS$69.30k0.18%
$ 19.8k
William Facteau
Independent Directorless than a yearno datano data
Simon Stertzer
Independent Director22.2yrsUS$60.80k5.75%
$ 624.4k
Jim Allen
Independent Director4.4yrsUS$60.80k3.45%
$ 375.1k
Andrew Blank
Independent Chairman4.4yrsUS$109.30k1.94%
$ 210.8k

7.4yrs

Average Tenure

67yo

Average Age

Experienced Board: BCDA's board of directors are considered experienced (7.4 years average tenure).


Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.